Sign in
Taking peoplePhase 2

A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

Key facts

Who runs it
Shanghai BDgene Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
28 Apr 2025
Expected to end
Mar 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • BD111 Injection (investigational new drug)
  • Triple-drugs therapy of HSV-1 stromal keratitis
Record updated
18 May 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (29)Hide the full registry criteria

Who can take part

  • Aged 18 to 70 years old
  • Clinically diagnosed with herpes simplex virus stromal keratitis
  • Tear swab HSV-1 nucleic acid test (qPCR method) positive
  • No use of systemic antiviral drugs or corticosteroids within 48 hours before enrollment
  • No systemic immune eye diseases
  • Good eyelid structure and blinking function
  • Eye structure and function assessment showing potential for visual recovery
  • No retinal detachment, with generally normal visual function
  • No history of corneal trauma
  • Visual acuity in the fellow eye is better than 20/200
  • Fertile males or females must use highly effective contraceptive methods (such as oral contraceptives, intrauterine devices, abstinence, or barrier contraception combined with spermicides) during the trial and continue contraception for 12 months after administration
  • Participants voluntarily join the study, sign an informed consent form, have good compliance, and cooperate with follow-up visits

Who cannot take part

  • Active ocular infection caused by other pathogens in the target eye or the fellow eye within 30 days before enrollment, including but not limited to blepharitis, infectious conjunctivitis, keratitis, scleritis, and endophthalmitis
  • Previous corneal transplant surgery in the study eye
  • Participation in other drug or medical device clinical trials
  • Alcohol or drug abuse
  • Severe dry eye disease
  • Malignant ocular surface tumor
  • Patients with systemic autoimmune diseases
  • HIV infection
  • A history of adverse reactions or allergies to corticosteroids and sodium fluorescein, allergies to therapeutic or diagnostic protein products, allergies to ≥ two drugs or non-drug factors, or having an ongoing allergic disease
  • Signs of systemic infection before enrollment, including fever and receiving antibiotic treatment (abnormal elevating values in white blood cells, lymphocytes, and neutrophils in routine blood tests)
  • Abnormal major organ function or other uncontrolled clinical problems, mainly including but not limited to the following:; Severe kidney disease history, serum creatinine ≥ 133μmol/L; Liver dysfunction, transaminase level ≥ 80 IU/L; Uncontrolled hypertension, systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg; Uncontrolled diabetes, fasting blood glucose greater than or equal to 8.0 μmol/L; Cardiovascular disease history, with arrhythmia, myocardial ischemia, and myocardial infarction (diagnosed by electrocardiogram examination); Platelet level ≤ 100×10\^9/μL or ≥ 450×10\^9/μL due to any cause, hemoglobin level lower than 10.0g/dL (male) or 9.0g/dL (female)
  • Patients with bilateral viral keratitis
  • Absence of tear film and blinking function
  • Glaucoma
  • Pregnant and lactating women (pregnancy in this trial is defined as a positive urine pregnancy test)
  • Lack of compliance with the trial or the ability to sign an informed consent form
  • Other situations deemed unsuitable for participation in the trial by the investigator

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation of the clinical effectiveness of BD111 in combination with standard therapy.

The 2 groups in the trial

  • Group 1Treatment being tested

    BD111 combining triple-drugs therapy Group.

    Treatment: BD111 Injection (investigational new drug) and Triple-drugs therapy of HSV-1 stromal keratitis

  • Group 2Existing treatment, for comparison

    BD111 sham injection combining triple-drugs therapy group.

    Treatment: Triple-drugs therapy of HSV-1 stromal keratitis

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Single-blind, Single-dose, Randomized, Phase Ⅱa Trial to Evaluate the Safety, Tolerability and Efficacy of Intrastromal BD111 Gene Editing Therapy in Adults With HSV-1 Stromal Keratitis
Criteria questions
Built from NCT06474442, who can take part
Record updated
18 May 2025